Shattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

Rhea-AI Summary

Shattuck Labs, Inc. (NASDAQ: STTK) will participate in the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021. CEO Taylor Schreiber and CFO Andrew Neill will engage in a fireside chat at 1:50 p.m. EST. The event will be accessible via a live webcast, with a replay available for 90 days after the presentation. Shattuck specializes in developing bi-functional fusion proteins aimed at treating cancer and autoimmune diseases, leveraging their proprietary ARC® platform.

Positive

• Participation in a notable industry conference could enhance visibility and investor interest.
• Opportunity for executives to provide updates on pipeline developments and progress.

Negative

• None.

AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the 7^th Annual Truist Securities Life Sciences Summit being held virtually May 4-5, 2021.

Presentation Details
Conference: 7^th Annual Truist Securities Life Sciences Summit
Format: Fireside chat with analyst Asthika Goonewardene
Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, Shattuck’s Chief Financial Officer
Date: May 5, 2021
Time: 1:50 p.m. EST
Webcast Link: Available Here

A live webcast will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC^®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com

FAQ

What is the schedule for Shattuck Labs at the Truist Securities Life Sciences Summit?

Shattuck Labs will present on May 5, 2021, at 1:50 p.m. EST.

Who will represent Shattuck Labs at the summit?

CEO Taylor Schreiber and CFO Andrew Neill will represent the company.

How can I access the Shattuck Labs presentation?

The presentation will be available via live webcast, with a replay accessible for 90 days.

What is Shattuck Labs' focus in biotechnology?

Shattuck Labs focuses on developing bi-functional fusion proteins for cancer and autoimmune disease treatment.